Medicine and Dentistry
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
10%
Alpha 1 Antitrypsin
5%
Alpha 1-Antitrypsin Deficiency
5%
Antibiotic Therapy
5%
Asthma
6%
Atypical Mycobacterium
5%
Biological Marker
6%
Blood Analysis
6%
Blood Component
5%
Cardiovascular Disease
5%
Chest Tube
11%
Chronic Obstructive Pulmonary Disease
100%
Chronic Pulmonary Aspergillosis
5%
Clinical Trial
8%
Cohort Study
5%
Colorectal Carcinoma
5%
Conservative Treatment
5%
Cystic Fibrosis
5%
Diseases
8%
Echography
5%
Emergency Department
11%
Emphysema
5%
Eosinophil
9%
Hazard Ratio
5%
Human Monoclonal Antibody
7%
Immunoglobulin M
5%
Infectious Complication
5%
Iodine 131
5%
Leukopenia
5%
Lung
18%
Monoclonal Antibody
8%
Noninvasive Ventilation
17%
Open-Label Trial
11%
Oxygen Therapy
5%
Patient Referral
5%
Placebo
7%
Pneumothorax
6%
Prospective Cohort Study
6%
Pseudomonas aeruginosa
5%
Pulmonary Disorder
5%
Quality of Life
7%
Randomized Controlled Trial
16%
Recurrent Disease
7%
Respiratory Medicine
6%
Severe Asthma
5%
Silo-Filler's Disease
10%
Spontaneous Pneumothorax
17%
Surfactant Protein D
5%
Symptomatic Treatment
8%
Vitamin D
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Respiratory Failure
5%
All Cause Mortality
7%
Alpha 1 Antitrypsin
5%
Alpha 1 Antitrypsin Deficiency
5%
Antibiotic Therapy
5%
Antibiotics
5%
Asthma
11%
Atypical Mycobacterium
5%
Biological Marker
10%
Bronchiectasis
5%
Chronic Lung Disease
5%
Chronic Obstructive Lung Disease
98%
Clinical Trial
6%
Cohort Study
7%
Colorectal Carcinoma
5%
Cystic Fibrosis
5%
Diseases
6%
Human Monoclonal Antibody
8%
Immunoglobulin M
5%
Infectious Complication
5%
Interleukin 13
5%
Iodine-131
5%
Leukopenia
5%
Long Term Survival
5%
Lung Aspergillosis
5%
Lung Disease
9%
Monoclonal Antibody
9%
Mortality Rate
8%
Neoplasm
5%
Open-Label Trial
5%
Phosphatidylinositol 3 Kinase
5%
Placebo
7%
Postoperative Infection
5%
Prospective Cohort Study
5%
Pseudomonas aeruginosa
5%
Randomized Controlled Trial
10%
Respiratory Failure
6%
Respiratory Tract Inflammation
5%
Sepharose
5%
Surfactant Protein D
5%
Tralokinumab
5%
Vitamin D
5%
Volatile Organic Compound
5%
Nursing and Health Professions
Acute Respiratory Failure
5%
Alpha 1 Antitrypsin
5%
Alpha 1 Antitrypsin Deficiency
5%
Biological Marker
10%
Blood Culture
5%
Cannabis
5%
Cardiovascular Disease
5%
Emergency Ward
9%
Emphysema
5%
Health Practitioner
6%
Long Term Survival
5%
Medical Technician
11%
Noninvasive Ventilation
23%
Obstructive Lung Disease
56%
Patient Referral
5%
Spontaneous Pneumothorax
11%
Substitution Therapy
5%
Telemedicine
5%
Zymosan
5%
